Drug repurposing for Alzheimer's disease integrating transcriptome-wide association study and biological network analysis
Journal of Alzheimer’s Disease · 2025-09 · 107 (1) · 314-327
DOI: 10.1177/13872877251360009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 22.07.2025. Verfasst von Xin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Information Science and Engineering, Northeastern University, Shenyang, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Repositioning, Genome-Wide Association Study, Transcriptome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
The accumulation of particular protein deposits connected to molecular mechanisms is one of the many brain abnormalities associated with Alzheimer's disease (AD), a complex neurodegenerative illness. There are currently no effective disease-modifying treatments for AD.
Objective
This study attempts to identify potential AD therapeutics through a biological network-based drug repurposing strategy, focusing on drugs targeting important proteins and biological pathways involved in AD pathology.
Methods
A comprehensive biological network of AD-associated molecules and their transcription regulatory interactions is constructed. This computational approach integrates data from genome-wide association studies, multiple AD-related magnetic resonance imaging (MRI) derived phenotypes, biomolecular interactions, and gene expression profiles.
Results
The constructed AD sub-regulatory network reveals significant correlations between transcription factors showing changed gene expression in AD patients relative to controls. This strategy prioritizes drug candidates based on their mechanisms of action, reducing the risk of clinical trial failures and enhancing patient outcomes related to AD. A total of 43 drug candidates have been identified, including 28 FDA-approved drugs, 15 experimental and investigational drugs that may alter biological processes pertaining to important facets of AD pathology. Baricitinib and Gabapentin emerge as promising candidates for targeting AD-related biological processes in the cerebral cortex and hippocampus regions.
Conclusions
By combining biological network analysis and MRI-driven transcriptome-wide association study, this systematic drug repurposing strategy demonstrates promise for identifying novel therapeutic options for AD and offers potential implications for addressing other complex neurological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Information Science and Engineering, Northeastern University, Shenyang, China.
- Department of Statistics and Actuarial Science, School of Computing and Data Science, The University of Hong Kong, Hong Kong SAR, China.
- Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China.
- College of Science, China Agricultural University, Beijing, China.
ORCID-Profile: Xin Wang, Yan Dora Zhang
Zitieren
APA
Wang, X., Wang, M., Wang, H., Yin, G., & Zhang, Y. D. (2025). Drug repurposing for Alzheimer's disease integrating transcriptome-wide association study and biological network analysis. Journal of Alzheimer’s Disease, 107(1), 314-327. https://doi.org/10.1177/13872877251360009
Vancouver
Wang X, Wang M, Wang H, Yin G, Zhang YD. Drug repurposing for Alzheimer's disease integrating transcriptome-wide association study and biological network analysis. Journal of Alzheimer’s Disease. 2025;107(1):314-327. doi:10.1177/13872877251360009
BibTeX
@article{Wang2025,
author = {Wang, Xin and Wang, Meng and Wang, Han and Yin, Guosheng and Zhang, Yan Dora},
title = {Drug repurposing for Alzheimer's disease integrating transcriptome-wide association study and biological network analysis},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
volume = {107},
number = {1},
pages = {314--327},
doi = {10.1177/13872877251360009}
}
EUVIMED